Denosumab

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Denosumab
Klinički podaci
Robne marke Prolia, Ranmark, Xgeva
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 615258-40-7
ATC kod M05BX04
DrugBank DB06643
ChEMBL[1] CHEMBL1237023 YesY
Hemijski podaci
Formula C6404H9912N1724O2004S50 
Mol. masa 144.7
Farmakokinetički podaci
Poluvreme eliminacije 25,4 dana
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Subkutano
Denosumab

Denosumab[2] je ljudsko monoklonalno antitelo za tretman ostioporoze, gubitka koštane mase, koštanih metastaza, multiplog mijeloma, i tumora gigantskih ćelija kostiju.[3][4] Ovaj lek je razvilo biotehnološko preduzeće Amgen.[5] Denosumab je IgG2 monoklonalno antitelo koje je inhibira RANKL ligand.[6][7][8]

Reference[uredi - уреди | uredi izvor]

  1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  2. Pageau, Steven C. (2009). "Denosumab". MAbs 1 (3): 210–215. PMC 2726593. PMID 20065634. doi:10.4161/mabs.1.3.8592. 
  3. McClung, Michael R.; Lewiecki, E. Michael; Cohen, Stanley B.; Bolognese, Michael A.; Woodson, Grattan C.; Moffett, Alfred H.; Peacock, Munro; Miller, Paul D.; Lederman, Samuel N. (2006). "Denosumab in Postmenopausal Women with Low Bone Mineral Density". New England Journal of Medicine 354 (8): 821–31. PMID 16495394. doi:10.1056/NEJMoa044459. 
  4. Ellis, G. K.; Bone, H. G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Smith, J.; Fan, M.; Jun, S. (2008). "Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer". Journal of Clinical Oncology 26 (30): 4875–82. PMID 18725648. doi:10.1200/JCO.2008.16.3832. 
  5. "Prolia (denosumab)". Products. Amgen. http://www.amgen.com/medpro/products_prolia.html. pristupljeno 6. 5. 2012.. 
  6. Malan J, Ettinger K, Naumann E, Beirne OR: The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6. doi: 10.1016/j.oooo.2012.08.439. PMID 23159111
  7. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41. PMC 3013709. PMID 21059682. doi:10.1093/nar/gkq1126.  edit
  8. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic acids research 36 (Database issue): D901–6. PMC 2238889. PMID 18048412. doi:10.1093/nar/gkm958.  edit

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).